Araris Biotech AG
Araris Biotech AG is a wholly owned subsidiary of Taiho Pharmaceutical (part of the Otsuka Holdings), pioneering a novel, best-in-class technology platform generating multi-payload antibody-drug conjugates (ADCs) in one step on native antibodies, without requiring any antibody engineering or glycan remodelling. Araris ADCs have showed excellent stability and antibody-like PK properties, leading to higher efficacy and tolerability against multiple commercially available ADCs.
Date, time and room information
May 6, 12:30 - 12:45, room Singapore
Category
Emerging biotech company
Speaker information
| Name | Position | Institution |
|---|---|---|
| Filippo Mulinacci | Chief Business Officer | Araris Biotech AG, a wholly owned subsidiary of Taiho Pharmaceutical |
